ArticleNature2025
Engineered prime editors with minimal genomic errors.
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Prime Editing: An Overview.Methods in molecular biology (Clifton, N.J.) · 2027Review
- Advances in prime editing: Molecular innovations, Large-fragment engineering, and AI-driven design.Biodesign research · 2026Review
- On-target and off-target activities of CRISPR therapeutics across scales.Trends in biotechnology · 2026Review
- Reconfiguring biofortification strategies to transform food systems and address micronutrient deficiency of the 21st century.Journal of integrative plant biology · 2026Review
- vPE: Toward a new generation of error-free prime editing.Molecular therapy. Nucleic acids · 2026Article
- Multiplexed, precise genome engineering in monocots with twin prime editing systems.Nature biotechnology · 2026Article
- A primer on prime: A prime editing update from advances to first-in-human trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications.BMB reports · 2026Review
- Article
- Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA.Genes · 2026Review
- Evolution of Prime Editing: Enhancing Efficiency and Expanding Capacity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.Cancer cell international · 2026Review
- From Bench to Bedside: Ethical and Clinical Best Practices for Genome Editing Applications.International journal of molecular sciences · 2026Review
- Investigating and correcting a rare pathogenic mutation in GDF11.HGG advances · 2026Article
- Transposon-derived genome editors in plants: from compact nucleases to large-fragment integration and regeneration strategies.Engineering in life sciences · 2026Review
- LDLR variant classification through activity-normalized prime editing screening.bioRxiv : the preprint server for biology · 2025Article
- Gene Therapy of Beta Hemoglobinopathies.Biomedicines · 2025Review
- Base and Prime Editing for Inherited Retinal Diseases: Delivery Platforms, Safety, Efficacy, and Translational Perspectives.Pharmaceutics · 2025Review
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Prime editors make programmed genome modifications by writing new sequences into extensions of nicked DNA 3' ends
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.